Person: PEHLİVAN, YAVUZ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
PEHLİVAN
First Name
YAVUZ
Name
64 results
Search Results
Now showing 1 - 10 of 64
Publication Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries(Wiley, 2022-04-29) Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Gudbjornsson, Bjorn; Codreanu, Catalin; Yılmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Moeller, Burkhard; Favalli, Ennio G.; Sanchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Love, Thorvardur J.; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; Van der Horst-Bruinsma, Irene; Ornbjerg, Lykke M.; Ostergaard, Mikkel; Hetland, Merete L.; PEHLİVAN, YAVUZ; Tıp Fakültesi; AAG-8227-2021Objective There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall and across 1) number of prior biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), 2) years since diagnosis, and 3) European registries. Methods Thirteen quality registries in rheumatology participating in the European Spondyloarthritis Research Collaboration Network provided longitudinal, observational data collected as part of routine care for secondary use. Data were pooled and analyzed with Kaplan-Meier plots, log rank tests, Cox regression, and multiple linear and logistic regression analyses. Results A total of 2,017 PsA patients started treatment with secukinumab between 2015 and 2018. Overall secukinumab retention rates were 86% and 76% after 6 and 12 months, respectively. Crude (LUNDEX adjusted) 6-month remission/LDA (LDA including remission) rates for the 28-joint Disease Activity Index for Psoriatic Arthritis, the Disease Activity Score in 28 joints using the C-reactive protein level, and the Simplified Disease Activity Index (SDAI) were 13%/46% (11%/39%), 36%/55% (30%/46%), and 13%/56% (11%/47%), and 12-month rates were 11%/46% (7%/31%), 39%/56% (26%/38%), and 16%/62% (10%/41%), respectively. Clinical Disease Activity Index remission/LDA rates were similar to the SDAI rates. Six-month American College of Rheumatology 20%/50%/70% improvement criteria responses were 34%/19%/11% (29%/16%/9%); 12-month rates were 37%/21%/11% (24%/14%/7%). Secukinumab effectiveness was significantly better for b/tsDMARD-naive patients, similar across time since diagnosis (4 years), and varied significantly across the European registries. Conclusion In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to that in previous observational studies of tumor necrosis factor inhibitors. Retention, remission, LDA, and response rates were significantly better for b/tsDMARD-naive patients, were independent of time since diagnosis, and varied significantly across the European countries.Publication Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib(BMJ Publishing Group, 2022-06-01) İnanç, N.; Abacar, K.; Öztürk, M. A.; Tufan, A.; Karadeniz, H.; Sarı, I.; Can, G.; Erez, Y.; Pehlivan, Yavuz; Dalkılıç, Ediz; Ocak, Tuğba; Cefle, A.; Yazıcı, A.; Şenel, A.; Akar, S.; Ediboğlu, E. Durak; Koca, S. S.; Sağır, R. Pişkin; Yılmaz, S.; Gülcemal, S.; Gündüz, O. Soysal; Başıbüyük, C. S.; Alkan, S.; Cesur, T. Y.; Önen, F.; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; OCAK, TUĞBA; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Romatoloji Bilim Dalı; FQP-0451-2022; JHC-5173-2023; FPQ-5941-2022Publication Inflammatory back pain due to heterotopic ossification(Aves, 2014-09-01) Kimyon, Gezmis; Pehlivan, Yavuz; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; AAG-8227-2021Publication Malignancy risk in systemic lupus erythematosus patients treated with cyclophosphamide(Clinical & Exper Rheumatology, 2015-05-01) Yilmaz, N.; Emmungil, H.; Gücenmez, S.; Özen, G.; Yıldız, F.; Balkarlı, A.; Kimyon, G.; Coşkun, B. Necdet; Doğan, I.; Pamuk, O. N.; Yaşar, S.; Cetin, G. Yildirim; Yazıcı, A.; Esmen, S. Ergülü; Cağatay, Y.; Yılmaz, S.; Celle, A.; Cefle, A.; Sayarhoğlu, M.; Kaşifoğlu, T.; Karadağ, O.; Pehlivan, Yavuz; Dalkılıç, Ediz; Kısacık, B.; Cobankara, V.; Erken, E.; Direskeneli, H.; Aksu, K.; Yavuz, S.; COŞKUN, NEJDET; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Romatoloji Bölümü; 0000-0003-0298-4157; ETE-5180-2022; AAG-8227-2021; AAG-7155-2021Publication Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic(TÜBİTAK, 2021-01-01) Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, Gezmiş; Karadağ, Ömer; Dalkılıç, Ediz; Ertenli, Ali İhsan; Kılıç, Levent; Ersözlü, Duygu; Beş, Cemal; Emmungil, Hakan; Mercan, Rıdvan; Ediboğlu, Elif Durak; Kanıtez, Nilüfer; Bilgin, Emre; Çolak, Seda; Koca, Süleyman Serdar; Gönüllü, Emel; Küçükşahin, Orhan; Coşkun, Nihan; Yağız, Burcu; Kiraz, Sedat; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; COŞKUN, BELKIS NİHAN; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; 0000-0002-3734-1242; 0000-0003-1372-1555; 0000-0001-5184-4404; 0000-0003-1185-5816; 0000-0002-2260-4660; 0000-0003-4995-430X; 0000-0002-6990-4206; W-7332-2019; AAK-7851-2021; AAD-5448-2019; AAZ-5845-2021; AAG-8227-2021; C-8092-2015; JQW-5031-2023; GZA-3287-2022Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6-9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients' data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21-73] vs. 44 years [20-79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.Publication The effect of rheumatoid factor and anti-cyclic citrullinated peptide positivity on drug survival of abatacept in patients with rheumatoid arthritis in routine care: The results from turkbio registry(Wiley, 2015-10-01) Ertenli, İhsan; Karadağ, Ömer; Pehlivan, Yavuz; Dalkılıç, Ediz; Onat, Ahmet Mesut; Kısacık, Bünyamin; Can, Gerçek; Akar, Servet; Çapar, Sedat; Kalyoncu, Ümut; Öksüz, Mustafa Ferhat; Tarhan, Emine Figen; Akkoç, Nurullah; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Oksuz, Mustafa Ferhat; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; AAG-8227-2021; CMF-4757-2022; JXF-7598-2024Publication Covid-19 vaccination of spondyloarthritis patients receiving biological therapy: Real-life data(BMJ Publishing Group, 2022-06-01) Yıldırım, T. Demirci; Akleylek, C.; Cinakli, H.; Yildirim, D.; Hakbilen, S.; Coşkun, B. N.; Okyar, B.; Işık, O. Ozdemir; Sağir, R. Piskin; Apaydin, H.; Gülle, S.; Erez, Y.; İnel, T. Yuce; Yilmaz, N.; Akar, S.; Tufan, A.; Yılmaz, S.; Pehlivan, Yavuz; Cetin, G. Yildirim; Cefle, A.; Koca, S. S.; Erten, S.; Yazici, A.; Dalkılıç, Ediz; Can, G.; Sari, I.; Birlik, M.; Önen, F.; COŞKUN, NEJDET; PEHLİVAN, YAVUZ; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Ramatoloji Bölümü; JHC-5173-2023; FQP-0451-2022; AAG-7155-2021Publication Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: A case-based review(Springer Heidelberg, 2019-12-01) Coşkun, Belkıs Nihan; COŞKUN, BELKIS NİHAN; Yağız, Burcu; YAĞIZ, BURCU; Pehlivan, Yavuz; PEHLİVAN, YAVUZ; Dalkılıç, Ediz; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; AAG-7155-2021; AAG-8227-2021; JQW-5031-2023Hidradenitis suppurativa (HS) is a chronic, suppurative skin disease characterized by painful nodules, particularly in the axillae and groin. Isotretinoin can be used in the treatment of HS; however, it may paradoxically lead to skin lesions or worsen the existing lesions. Isotretinoin, which is commonly used in the treatment of severe acne, is associated with several side effects, including rheumatic side effects and rarely sacroiliitis. In this study, we discussed two cases who presented with low back pain after isotretinoin was used for the treatment of acne vulgaris. The patients did not have low back pain before isotretinoin use and did not have enthesitis, dactylitis, uveitis, psoriasis, recent infection, trauma, and family history spondylitis. HLA-B27 was negative. Bone-marrow edema was detected at the sacroiliac joint on magnetic resonance imaging. Because of these findings, sacroiliitis related to the drug was considered in our patients and isotretinoin treatments were discontinued. Because the patients' low back pain continued when they administered non-steroidal anti-inflammatory drugs, biological drug treatments were started. Both cases presented had a simultaneous HS lesion. After the treatment, both low back pain and HS lesions regressed. Patients with isotretinoin therapy should be alerted for inflammatory low back pain and HS lesions that may develop. We should note that biologic agents should be considered in the treatment of resistant cases.Publication Cigarette smoking does not affect treatment response to tofacitinib in rheumatoid arthritis(Wiley, 2018-09-01) Karataş, Ahmet; Öz, Burak; Dalkılıç, Ediz; Can, Gerçek; Pehlivan, Yavuz; Şenel, Soner; Yazıcı, Ayten; İnanç, Nevsun; Ertürk, Zeynep; Cefle, Ayşe; Akar, Servet; Koca, Süleyman Serdar; Birlik, Merih; Önen, Fatoş; DALKILIÇ, HÜSEYİN EDİZ; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Bölümü; CMF-4757-2022; AAG-8227-2021Publication Characteristics of patients who received biological treatment after kidney transplantation and the incidence of serious infections: A multicenter study(Bmj Publishing Group, 2023-06-01) Yıldırım, T. Demirci; Kökoğlu, E. Oğuz; Coşkun, B. N.; Yıldırım, D.; Şenel, S.; Pehlivan, Y.; Küçük, H.; Kaşifoğlu, T.; Sarı, I.; COŞKUN, BELKIS NİHAN; PEHLİVAN, YAVUZ; Tıp Fakültesi; Romatoloji Ana Bilim Dalı; KIW-0794-2024; FQP-0451-2022